Are peptides safe in pregnancy, and before trying to conceive?
Reviewed 19 sourcesPublished by PepVault
Are peptides safe in pregnancy? Each label's pregnancy and birth-control line in one table, Wegovy to Vyleesi, with half-lives and BPC-157's missing data.

- Last reviewed
- Sources
- 19
- Questions
- 7
- Compounds
- 14
The short answer
No peptide taken for weight, fat, healing or growth hormone is labelled safe in pregnancy. Tesamorelin is contraindicated; Wegovy, Zepbound and Saxenda say stop once a pregnancy is known; Ozempic and Mounjaro, for diabetes, leave a benefit-risk call. Only the two semaglutide labels set a date: 2 months before a planned pregnancy. BPC-157 and TB-500 have no human pregnancy data. Your prescriber sets the plan.
Evidence: FDA labels (DailyMed) for twelve approved peptide medicines, with their animal reproduction studies and small human pregnancy counts, and human pharmacokinetic studies for the half-lives; none of the weight, fat, sex-drive, growth-hormone or healing peptides here has been tested in a pregnancy trial, and research peptides have no human pregnancy data.

Are any peptides used in pregnancy?
Yes, and that is why the word "peptide" alone does not answer the question. A peptide is a short chain of amino acids, and two of the most-used medicines in pregnancy are peptides. Insulin is one: the label for Novo Nordisk's insulin aspart notes that randomised trials in the second trimester found no link with major birth defects, while poorly controlled diabetes carries real risks for mother and baby13. Oxytocin is the other. Hospitals give it as Pitocin to start or strengthen labour, and its label says that, used as indicated, it would not be expected to cause fetal abnormalities14.
So the answer belongs to each drug, not to the class. For the peptides people take for weight, belly fat, sex drive, growth hormone or healing, human pregnancy data are thin or absent, so the labels' warnings rest on animal reproduction studies and, for the weight and fat drugs, on the plain point that losing weight brings a pregnancy no benefit. Most of those labels tell you to stop or avoid them. The research peptides have no label at all.

What does each peptide's label say about pregnancy and birth control?
Here is the pregnancy and contraception line of every approved peptide people most often ask about, from the FDA labels on DailyMed as of November 20, 2026. A contraindication is the strongest word a label has: do not use.
| Label (peptide) | Once pregnant | Before a planned pregnancy | Birth control |
|---|---|---|---|
| Ozempic (semaglutide, diabetes) | Use only if the benefit justifies the risk to the fetus1 | Stop at least 2 months before1 | No step on the label1 |
| Wegovy (semaglutide, weight) | Stop when pregnancy is recognized; for MASH, a liver disease, only if the benefit justifies the risk2 | Stop at least 2 months before; for MASH, when the risk outweighs the benefit2 | No step on the label2 |
| Mounjaro (tirzepatide, diabetes) | Use only if the benefit justifies the risk to the fetus3 | No interval stated3 | On the pill: switch to a non-oral method, or add a barrier, for 4 weeks after starting and after each dose increase3 |
| Zepbound (tirzepatide, weight) | Stop when pregnancy is recognized4 | No interval stated4 | The same 4-week pill step as Mounjaro4 |
| Saxenda (liraglutide, weight) | Stop when pregnancy is recognized5 | No interval stated5 | No step; in a pill study, overall estrogen exposure was unchanged5 |
| Egrifta SV and WR (tesamorelin) | Contraindicated; stop if pregnancy occurs67 | No interval stated6 | No step on the label6 |
| Vyleesi (bremelanotide, PT-141) | Stop if pregnancy is even suspected8 | No interval stated8 | Use effective contraception while taking it8 |
| Imcivree (setmelanotide) | Stop when pregnancy is recognized, unless the benefit outweighs the risk9 | No interval stated9 | No step on the label9 |
| Novarel and Pregnyl (hCG) | Novarel: may cause fetal harm; Pregnyl: not indicated, stopped once pregnancy is confirmed1011 | A fertility drug: used to bring on ovulation10 | No step on the label10 |
| Genotropin (somatropin, HGH) | Data too limited to judge a risk12 | No interval stated12 | No step on the label12 |
The pattern follows each drug's job. Where the goal is weight, the labels say plainly that weight loss "offers no benefit to a pregnant patient and may cause fetal harm"245; Egrifta's says the same of shrinking belly fat6. Where the drug treats diabetes, uncontrolled blood sugar is a risk of its own, so the Ozempic and Mounjaro labels leave a weighing of benefit and risk to the prescriber13.
The animal results behind the warnings differ widely. Tesamorelin caused hydrocephaly, fluid on the brain, in rat offspring at about two to four times the clinical exposure6. Bremelanotide raised pregnancy loss in dogs at 16 times the human exposure and above8. Setmelanotide and somatropin are the calm ones: no embryo-fetal harm in rats at up to 11 times human exposure for setmelanotide9, none in rats or rabbits at about 19 to 24 times human doses for somatropin12. For the GLP-1 drugs in depth, with the exposure studies and breastfeeding, read pepvault.app/guides/glp-1s-and-pregnancy; metformin and LDN have their own pregnancy guides.
Is BPC-157 or TB-500 safe in pregnancy?
Nobody knows, and that is the plain state of the evidence. BPC-157, TB-500, CJC-1295, ipamorelin and injected GHK-Cu have no FDA label, so there is no pregnancy section to read. Retatrutide, still in Lilly's trials, has no label yet either.
A 2025 systematic review of BPC-157 gathered 36 studies: 35 in animals or cells and one in people, 12 patients with knee pain. It found no clinical safety data in humans, let alone in pregnancy15. The animal safety studies it read reported no harm across several organ systems; those are animal results15. A research peptide has no label summing up animal reproduction studies like the rat, rabbit and dog work quoted above, and the review adds that harm is possible from unregulated manufacturing and contamination as well as from unknown safety15. The human studies that do exist are in pepvault.app/guides/bpc-157-human-data.
How long do peptides stay in your body before trying to conceive?
That depends on the half-life, the time for half of the drug in the blood to be cleared (pepvault.app/glossary/half-life). After one half-life half remains; after five, about 3%. The spread across peptides is huge, from minutes for tesamorelin to about a week for semaglutide.
| Peptide | Half-life in people | Five half-lives (about 97% gone) |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | About 1 week12 | About 5 weeks; the Wegovy label says 5 to 7 weeks2 |
| Retatrutide | About 6 days, in a phase 1b trial16 | About 30 days |
| Tirzepatide (Mounjaro, Zepbound) | About 5 days; 5 to 6 days with obesity34 | 25 to 30 days |
| CJC-1295 with DAC | 5.8 to 8.1 days17 | 29 to 41 days |
| hCG | 32 to 33 hours18 | About 7 days |
| Liraglutide (Saxenda) | About 13 hours5 | About 3 days |
| Setmelanotide (Imcivree) | About 11 hours9 | About 2 days |
| Somatropin (HGH) | 3 hours under the skin12 | About 15 hours |
| Bremelanotide (PT-141) | About 2.7 hours8 | About 14 hours |
| Ipamorelin | 2 hours, by vein in healthy men19 | About 10 hours |
| Tesamorelin (Egrifta) | 8 to 11 minutes67 | Under an hour |
| BPC-157 | Not measured in people; under 30 minutes in animals15 | No human figure |
Read the right-hand column as arithmetic, not as a stop date. Only semaglutide's labels turn it into one: their 2 months covers the 5 weeks (Ozempic) to 5 to 7 weeks (Wegovy) it stays in the blood, with a margin12. The effect can also outlast the drug: after repeated doses of CJC-1295 with DAC, IGF-1, the growth factor it raises, stayed above baseline for up to 28 days17. Each compound's own page shows the curve, for example pepvault.app/peptides/tirzepatide/half-life and pepvault.app/peptides/bpc-157/half-life. Which date applies to you is your prescriber's decision.
PepVault's dose log keeps the date and amount of every dose you log, for each compound, so your last dose is on record when your prescriber asks how long it has been. Log it in PepVault
Do men need to stop peptides before trying to conceive?
No label in the table sets a stop date for a man. Their stop-before and birth-control lines are written for the person who will carry the pregnancy12348. What the labels hold for men are rat fertility studies. Semaglutide had no effect on male fertility1, tirzepatide none on sperm shape, mating or conception3, liraglutide no direct effect at 11 times human exposure5, and tesamorelin none in male or female rats6.
Somatropin is the exception at high doses: at about 24 times the human dose, male rats made fewer and less motile sperm, with no effect at about 2 times12. All of these are rat results. hCG runs the other way, as a fertility treatment: its label lists it for men whose low testosterone comes from the pituitary (pepvault.app/peptides/hcg)10. For BPC-157 there are no human safety data of any kind, in men or women15.
What if you find out you're pregnant while taking a peptide?
It most often happens in the weeks before a positive test. The labels' first step is the same: stop the weight and fat drugs once the pregnancy is known (Wegovy, Zepbound, Saxenda, Egrifta), stop Vyleesi if pregnancy is even suspected, and stop Imcivree unless the benefit outweighs the risk245689. On a diabetes drug such as Ozempic or Mounjaro, the call is the prescriber's, because blood sugar control matters for the baby too13.
The human numbers are small. Across Vyleesi's trials in more than 1,057 women, 7 pregnancies were reported: no major birth defects, five full-term births, one miscarriage and one lost to follow-up8. For scale, the labels give the background risk in any US pregnancy: 2% to 4% for a major birth defect and 15% to 20% for a miscarriage8. Wegovy and Zepbound each run a pregnancy registry that collects outcomes, and their labels ask exposed patients to report to it24.
Commonly reported: surprise pregnancies after the weight came off on a GLP-1, worry after a few weeks of BPC-157 before a positive test, and confusion over how long to wait after a research peptide, a question no label answers.
When to get help A positive test while taking any of these is a reason to call your prescriber or obstetrician that week, and anyone taking a peptide for diabetes should ask before stopping it.
What should you ask your prescriber before trying to conceive?
- Which of my peptides has an FDA label, and what does its pregnancy section say?
- If I take semaglutide, which day should my last dose be, given the label's 2 months?
- If I take the pill and start or step up tirzepatide, what do I use for the 4 weeks after?
- For a research peptide with no label, how long should I stop before trying, and on what basis?
- If I take a peptide for diabetes, what replaces it before and during pregnancy?
- Does my partner need to stop anything?
PepVault's doctor's report lists each compound with the doses you logged, so you can bring the whole picture to that appointment on one page. Log it in PepVault
Next, read pepvault.app/guides/glp-1s-and-pregnancy for the semaglutide and tirzepatide studies in full.
Sources
- Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information (DailyMed, SPL version 20, effective Jun 1, 2026): sections 8.1, 8.3, 12.3 and 13.1. dailymed.nlm.nih.gov
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (DailyMed, SPL version 19, effective Jun 18, 2026): sections 8.1, 8.3, 12.3 and 13.1. dailymed.nlm.nih.gov
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information (DailyMed, SPL version 40, effective Aug 27, 2026): sections 7.2, 8.1, 8.3, 12.3 and 13.1. dailymed.nlm.nih.gov
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information (DailyMed, SPL version 40, effective Aug 28, 2026): sections 7.2, 8.1, 8.3, 12.3 and 13.1. dailymed.nlm.nih.gov
- Novo Nordisk. SAXENDA (liraglutide) injection, prescribing information (DailyMed, SPL version 22, effective Feb 25, 2026): sections 8.1, 12.3 and 13.1. dailymed.nlm.nih.gov
- Theratechnologies. EGRIFTA SV (tesamorelin) for injection, prescribing information (DailyMed, SPL version 9, effective Jul 29, 2026): sections 4, 8.1, 12.3 and 13.1. dailymed.nlm.nih.gov
- Theratechnologies. EGRIFTA WR (tesamorelin) for injection, prescribing information (DailyMed, SPL version 2, effective Jul 29, 2026): sections 4, 8.1 and 12.3. dailymed.nlm.nih.gov
- Cosette Pharmaceuticals. VYLEESI (bremelanotide) injection, prescribing information (DailyMed, SPL version 2, effective Nov 5, 2026): sections 8.1, 8.3 and 12.3. dailymed.nlm.nih.gov
- Rhythm Pharmaceuticals. IMCIVREE (setmelanotide) injection, prescribing information (DailyMed, SPL version 14, effective Apr 1, 2026): sections 8.1 and 12.3. dailymed.nlm.nih.gov
- Ferring Pharmaceuticals. NOVAREL (chorionic gonadotropin) for injection, prescribing information (DailyMed, SPL version 41, effective Aug 27, 2025): indications, contraindications and pregnancy. dailymed.nlm.nih.gov
- Organon. PREGNYL (chorionic gonadotropin) for injection, prescribing information (DailyMed, SPL version 11, effective Dec 2, 2025): pregnancy. dailymed.nlm.nih.gov
- Pfizer. GENOTROPIN (somatropin) for injection, prescribing information (DailyMed, SPL version 37, effective Aug 4, 2026): sections 8.1, 12.3 and 13.1. dailymed.nlm.nih.gov
- Novo Nordisk. NOVOLOG MIX 70/30 (insulin aspart protamine and insulin aspart) injection, prescribing information (DailyMed, SPL version 25, effective Feb 28, 2023): section 8.1. dailymed.nlm.nih.gov
- Par Health. PITOCIN (oxytocin) injection, prescribing information (DailyMed, SPL version 16, effective May 6, 2026): pregnancy. dailymed.nlm.nih.gov
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PubMed 40756949
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PubMed 36354040
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed 16352683
- Mannaerts BM, Geurts TB, Odink J. A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Hum Reprod. 1998;13(6):1461-1464. PubMed 9688371
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PubMed 10496658
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.